Kiromic BioPharma Inc. (OTC:KRBP) Stock In Focus After Recent Development

The trading week may be coming to a close, but investors are still going to be on the lookout for the next set of stocks that they may track, and one of the companies that they could consider looking into is Kiromic BioPharma Inc. (OTC:KRBP). It is a fully integrated clinical-stage biotherapeutics firm that deploys its proprietary DIAMOND artificial intelligence and data mining platform for the development of cell therapies. Those therapies are focused on immuno-oncology.

On Thursday, the company was in focus after it announced that it had been successful in its effort to uplist its stock to the OTCQB Venture Market from the OTC Pink Market. It was also noted that the stock would start trading on the OTCQB Venture Market from the start of trading on November 17, 2023. However, it was also noted that the company would continue to trade under the usual ticker symbol.

KRBP. The Chief Executive Officer of Kiromic BioPharma Inc., Pietro Bersani, spoke about the development as well. He noted that after having made the announcement about its plans for the OTCQB market, everyone at the company was delighted at having been able to uplist to the market following completion of all the necessary conditions. The latest move was also a testament to Kiromic BioPharma’s commitment to higher market visibility and transparency, he asserted. That would also provide the shareholders of the company with more opportunities as more and more potential investors show interest. He stated that the move would bring higher levels of attention to the stock from a larger volume of investors.

As an exchange, OTC Markets Group Inc. operates OTCQB, an exchange that is meant for entrepreneurial and developing companies in the United States and outside. Additionally, the exchange lists companies that also provide its investors with greater market visibility and transparency so as to boost liquidity. In order to become eligible for trading on the OTCQB, companies need to be current in their reporting with the OTC Markets Group and the United States Securities and Exchange Commission. The companies also need to go through a minimum bid price test, maintain audited financials through an audit firm, and also go through company verification as well as management verification on a yearly basis.

The company had been in the news cycle on November 16 as well, after it made a key announcement about its Deltacel Phase 1 clinical trial. Kiromic BioPharma announced at the time that it had started recruiting patients at the Beverly Hills Cancer Center (BHCC).

The study would work on evaluating the company product on patients suffering from metastatic non-small lung cancer. At the time, it was also announced by the company that it had continued to engage more clinical trial sites across the United States. It would provide updates with regards to the additional sites as and when they are activated. Additionally, updates would also be provided once patient recruitment begins at those same locations. It may be a good time to keep an eye on the stock.